Spontaneous apoptosis of CD8+ T lymphocytes in peripheral blood of patients with advanced melanoma

Clinical Cancer Research

Volumn 6, Issue 4, 2000, Pages 1351-1364

  Saito, Takao ^a   Dworacki, Grzegorz ^a,b   Gooding, William ^a   Lotze, Michael T ^a,b   Whiteside, Theresa L ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ANTIBODY; CASPASE 3; CD3 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 4; LIPOCORTIN 5; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ADVANCED CANCER; AGED; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MALE; MELANOMA; PRIORITY JOURNAL; SUPPRESSOR CELL;

ADULT; AGED; ANNEXIN A5; ANTIGENS, CD; ANTIGENS, CD14; ANTIGENS, CD19; ANTIGENS, CD3; ANTIGENS, CD4; ANTIGENS, CD56; ANTIGENS, CD8; ANTIGENS, CD95; APOPTOSIS; CASPASE 3; CASPASES; CD8-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; DNA FRAGMENTATION; FEMALE; FLOW CYTOMETRY; HUMANS; IN SITU NICK-END LABELING; LEUKOCYTES, MONONUCLEAR; MALE; MELANOMA; MIDDLE AGED; PROTEIN BINDING; RECEPTORS, IGG; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I;

EID: 0034048905     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Anichini, A., Fossati, G., and Parmiani, G. Clonal analysis of cytotoxic T lymphocyte response to autologous human melanoma. Int. J. Cancer, 35: 683-689, 1985.
2. Miescher, S., Whiteside, T. L., Von Carrell, S., and Fliedner, V. Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes. J. Immunol., 136: 1899-1907, 1986.
3. Rabinowich, H., Banks, M., Reichert, T., Logan, T. F., Kirkwood, J. M., and Whiteside, T. L. Expression and activity of signaling molecules in T lymphocytes obtained from patients with melanoma before and after IL-2 therapy. Clin. Cancer Res., 2: 1263-1274, 1996.
4. Zea, A. H., Brendan, C. D., Longo, D. L., Alvord, W. G., Strobl, S. L., Mizoguchi, H., Creekmore, S. P., O'Shea, J. J., Powers, G. C., Urba, W. J., and Ochoa, A. C. Alterations in T-cell receptor and signal transduction molecules in melanoma patients. Clin. Cancer Res., 1: 1327-1335, 1995.
5. Reichert, T. E., Rabinowich, H., Johnson, J. T., and Whiteside, T. L. Human immune cells in the tumor microenvironment: mechanisms responsible for signaling and functional defects. J. Immunother., 21: 295-306, 1998.
6. Ochoa, A. C., and Longo, D. L. Alteration of signal transduction in T cells from cancer patients. In: V. T. DeVita, S. Hellman, and S. A. Rosenberg (eds.), Important Advances in Oncology, pp. 43-54. Philadelphia: J. B. Lippincott Co., 1995.
7. + T lymphocytes infiltrating human solid tumors. Cancer Res., 48: 6992-6998, 1988.
8. Lai, P., Rabinowich, H., Crowley-Nowick, P. A., Bell, M. C., Mantovani, G., and Whiteside, T. L. Alterations in expression and function of signal transduction proteins in tumor associated NK and T lymphocytes from patients with ovarian carcinoma. Clin. Cancer Res., 2: 161-173, 1996.
9. Whiteside, T. L., and Rabinowich, H. The role of Fas/FasL in immunosuppression induced by human tumors. Cancer Immunol. Immunother., 46: 175-184, 1998.
10. Rabinowich, H., Reichert, T. E., Kashii, Y., Bell, M. C., and Whiteside, T. L. Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells: implications for altered expression of TcR in tumor-associated lymphocytes. J. Clin. Investig., 101: 2579-2588, 1998.
11. Reichert, T. E., Day, R., Wagner, E. M., and Whiteside, T. L. Absence of low expression of the ζ chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma. Cancer Res., 58: 5344-5347, 1998.
12. Gastman, B. R., Atarashi, Y., Reichert, T. E., Saito, T., Balkir, L., Rabinowich, H., and Whiteside, T. L. Fas ligand is expressed on human squamous cell carcinomas of the head and neck and it promotes apoptosis of T lymphocytes. Cancer Res., 59: 5556-5364, 1999.
13. Gastman, B. R., Johnson, D. E., Whiteside, T. L., and Rabinowich, H. Caspase-mediated degradation of TCR-ζ chain. Cancer Res., 59: 1422-1427, 1999.
14. Whiteside, T. L. Signaling defects in T lymphocytes of patients with malignancy. Cancer Immunol. Immunother., 48: 401-410, 1999.
15. Saito, T., Kuss, I., Dworacki, G., Gooding, W., Johnson, J. T., and Whiteside, T. L. Spontaneous ex vivo apoptosis of peripheral blood mononuclear cells in patients with head and neck cancer. Clin. Cancer Res., 5: 1263-1273, 1999.
16. Darzynkiewicz, Z., Brumo, S., Del Bino, G., Gorczyca, W., Hotz, M. A., Lassota, P., and Traganos, F. Features of apoptotic cells measured by flow cytometry. Cytometry, 13: 795-808, 1992.
17. Vermes, I., Haanen, C., Steffens-Nakken, H., and Reutelingsperger, C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J. Immunol. Methods, 184: 39-51, 1995.
18. Zapata, J. M., Takahashi, R., Salvesen, G. S., and Reed, J. C. Granzyme release and caspase activation in activated human T-lymphocytes. J. Biol. Chem., 273: 6916-6920, 1998.
19. Whiteside, T. L. Tumor-Infiltrating Lymphocytes in Human Solid Tumors. Austin, TX: R. G. Landes, 1993.
20. Gastman, B. R., Johnson, D. E., Whiteside, T. L., and Rabinowich, H. Tumor-induced apoptosis of T lymphocytes: elucidation of intracellular apoptotic events. Blood, 95: 2015-2023, 2000.
21. Lee, P. P., Yee, C., Savage, P. A., Fong, L., Brockstedt, D., Weber, J. S., Johnson, D., Swetter, S., Thompson, J., Greenberg, P. D., Roederer, M., and Davis, M. M. Characterization of circulating T cells specific tor tumor-associated antigens in melanoma patients. Nat. Med., 5: 677-685, 1999.
22. Chappell, D. B., and Restifo, N. P. T cell-tumor cell: a fatal interaction? Cancer Immunol. Immunother., 47: 65-71, 1998.
23. Zaks, T. Z., Chappell, D. B., Rosenberg, S. A., and Restifo, N. P. Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition. J. Immunol., 162: 3273-3279, 1999.
24. Walker, P. R., Saas, P., and Dietrich, P-Y. Tumor expression of Fas ligand (CD 95L) and the consequences. Curr. Opin. Immunol., 10: 564-572, 1998.
25. Hahne, M., Rimoldi, D., Schroter, M., Romero, P., Schreier, M., French, L. E., Schneider, P., Bornard, T., Fontana, A., Lienard, D., Cerottini, J-C., and Tschopp, J. Melanoma cell expression of Fas (Apo-1/CD95) ligand-implications for tumor immune escape. Science (Washington DC), 274: 4521-4524, 1996.
26. Shiraki, K., Tsuji, N., Shiroda, T., and Isselbacher, H. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc. Natl. Acad. Sci. USA, 94: 6420-6425, 1997.
27. Chappell, D. B., Zaks, T. Z., Rosenberg, S. A., and Restifo, N. P. Human melanoma cells do not express Fas (Apo-1/CD95) ligand. Cancer Res., 59: 59-62, 1999.
28. Smith, S. W., and Osborne, B. A. Private pathways to a common death. J. NIH Res., 9: 33-37, 1997.
29. Donnenberg, A. D., and Margolick, J. B. T-cell homeostasis in HIV-1 infection. Semin. Immunol., 9: 381-388, 1997.
30. + T cell turnover in HIV-1 infection: a paradigm revisited. Immunol. Today, 19: 44-48, 1998.